Pecavaptan

Cat. No.: HY-109133

CAS No.: 1914998-56-3

Molecular Formula: $C_{22}H_{19}Cl_2F_3N_6O_3$

Molecular Weight: 543.33

Target: Vasopressin Receptor

Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pecavaptan is an orally active and dual antagonist of V1a/V2 receptor (K_i=0.5 nM and 0.6 nM for human, respectively). Pecavaptan promotes an increase in urine production, which reduces the associated symptoms of water retention and edema[1].			
IC_{50} & Target	human V1a Receptor 3.6 nM (IC_{50})	canine V1a Receptor 4.4 nM (IC_{50})	human V2 Receptor 1.7 nM (IC_{50})	canine V2 Receptor 1.3 nM (IC_{50})
In Vivo	Pecavaptan (0.01, 0.03, 0.1 and 0.3 mg/kg; IV; single dose) protects from arginine vasopressin (AVP)-mediated cardiac output (CO) in canine tachypacing-induced model of heart failure (HF)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Mondritzki T, et al. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. Eur J Heart Fail. 2021 May;23(5):743-750.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA